Surrozen Inc. (SRZNW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Surrozen Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 833,333 | $950,000.04 | $12,999.99 | -$937,000.05 | -98.63% |
| BO Brian Oliveira Clear Street Group Inc. | 100 | $2 | $1.7 | -$0.3 | -15% |
Surrozen Inc. (SRZNW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Surrozen Inc. ever had a stock split?
Surrozen Inc. Profile
| Biotechnology Industry | Healthcare Sector | Craig C. Parker CEO | NASDAQ (CM) Exchange | 86889P117 CUSIP |
| US Country | 44 Employees | - Last Dividend | - Last Split | 12 Aug 2021 IPO Date |
Overview
Surrozen, Inc. is a pioneering force in the biotechnology sector, concentrating its efforts on the discovery and development of innovative drug candidates. These candidates are designed to selectively modulate the Wnt pathway, a critical axis in the regulation of tissue repair and regeneration. Founded in 2015 and headquartered in South San Francisco, California, Surrozen is at the forefront of developing antibody-based therapeutics. The company's focus spans a broad range of disease areas, including but not limited to conditions affecting the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. In its quest to address unmet medical needs, Surrozen has established a collaboration and license agreement with Boehringer Ingelheim International GmbH, aimed at advancing the research, development, and commercialization of Fzd4 bi-specific antibodies.
Products and Services
- SZN-043
A hepatocyte-specific R-spondin mimetic bispecific fusion protein, currently in Phase 1b clinical trial. SZN-043 is being developed for the treatment of severe liver diseases, such as alcoholic hepatitis. This product embodies Surrozen's commitment to leveraging cutting-edge scientific insights for the creation of therapies that address significant medical challenges in the field of liver diseases.
- SZN-1326
A bi-specific antibody that has advanced to Phase 1b clinical trial. SZN-1326 targets moderate to severe inflammatory bowel disease, aiming to provide a novel therapeutic option for patients grappling with this challenging condition. By focusing on Frizzled and LRP receptors, SZN-1326 represents a strategic effort to intervene in the biological pathways that contribute to inflammatory bowel diseases.
- SZN-413
Currently in the preclinical stage, SZN-413 is a Fzd4 targeted bi-specific antibody. This product is designed for the treatment of retinal vascular associated diseases, offering hope for novel treatments that could potentially address a range of conditions affecting the retina. The development of SZN-413 underscores Surrozen's dedication to expanding its portfolio into therapeutic areas of high unmet need, particularly in ophthalmology.
